



Interim Report of Egis Pharmaceuticals Public Limited Company

**October 1 – December 31, 2011
First Quarter***
(on the basis of
IFRS consolidated, non-audited balance sheet data)

**Egis Pharmaceuticals PLC's financial year extends from October 1 to September 30. Accordingly, the period from October 1 to December 31, 2011 was the first quarter of the 2011/2012 business year.*

EGIS PLC
Address: H-1106 Budapest, Keresztúri út 30–38.
Postal Address: H-1475 Budapest 10. P.O. Box 100
Phone number: (36-1) 265 5555, Telefax: (36-1) 265 5529

Summary

The first quarter of the 2011/2012 business year provided increasingly difficult market conditions, and at the same time, a more favourable forex environment for the Egis Group as a strongly export-orientated enterprise.

In the first quarter, the Group achieved **consolidated sales revenue of HUF 30,392mn**. This represents a figure **5% less** y/y. HUF value of sales revenue was raised by forex impact and reduced by market and seasonal effects.

In Hungary, which is one of the strategically important markets of the Egis Group, HUF value of the consolidated sales moved up 1% in the first quarter of the financial year. The Hungarian drug market saw a 1.3 per cent slow-down in the first quarter vs basis period. Regulation has become more burdensome. The manufacturer's price of pharmaceuticals has further decreased. With the elevated level of financial contributions to be paid by drug producers as from July 1, 2011, manufacturers take increasing part in covering reimbursement.

The EUR value of consolidated sales revenue showed an increase of 3% in Russia and other CIS markets and, due to turbulences caused by the changing drug market regulation in several countries, a 20% drop against the basis quarter of 2010/2011 in Eastern Europe. In other regions the turnover reached altogether 49% lower level y/y in EUR terms as a consequence of seasonal effects.

Consolidated gross profit came to **59.1%** of the sales revenue over the first quarter, reflecting a rise of 4.6 percentage points versus the comparative quarter. The growth of quarterly gross margin was caused primarily by forex rates and by the change in sales mix.

Consolidated sales, general and administration costs followed the dynamics of sales revenue lagging behind the comparative period's value by 5%. There was a positive development in the pharmaceutical R&D incentives. In this respect the Company reduced quarterly expenses by HUF 578mn.

In the first quarter the consolidated operating profit accounted for **HUF 5,522mn** which is 18.2% of sales revenue. This indicates a **15% expansion** y/y. The quarterly operating result achieved an outstanding level as an aggregate result of low costs and advantageous forex effects.

In the first quarter, consolidated profit resulting from financial activities together with the results of associated companies accounted for HUF 189mn. Thus **the consolidated pretax profit** came to **HUF 5,711mn, 8% higher** than a year ago. This is running into **18.8% of the sales revenue**.

According to the Company's assessment, the first three-month results can be qualified as expressly pleasing.

Sales Revenue – Domestic

In the first quarter the Egis Group achieved consolidated sales revenue of **HUF 8,917mn** in Hungary. This represents a **1% growth** y/y. According to IMS (International Medical Statistics) data, the Hungarian drug market experienced 1.3% set-back in value terms through the October - December 2011 period in comparison with the first quarter of 2010/2011. The market share of Egis Pharmaceuticals PLC in value terms accounted for 5.4% over this period. The Company continues to rank the fifth largest supplier in the domestic drug market.

Fierce price competition continued to prevail in the market of reimbursed products and especially, of generic drugs. The new price and reimbursement system introduced in the summer (so-called blind bidding process) caused further reductions in manufacturer's prices. Moreover, the National Health Insurance Fund further cut drug reimbursements. In order to maintain the reimbursement and market position of its products, also Egis Pharmaceuticals PLC followed the price trends in the market, and as from October 1, 2011 effected again price reduction of 6.9% on average in Hungary.

Payment obligation of drug producers on grounds of the reimbursements allocated to their drugs was raised up to 20% from 12% as from July 1, 2011. In the first three months, the amount payable by the Company according to the turnover came to HUF 744mn. As from July 1, the rate of registration fee on medical representatives is HUF 10mn/medrep/annum instead of HUF 5 million. On such grounds HUF 240mn payment obligation was accounted in the first quarter.

In December 2011, the Parliament restored for a definite period of time the R&D spending related deductibility option for payment obligations which had in June 2011 been ceased with retroactive effect. Resulting from the December 2011 modification of enactment, 90% of the payment obligation debiting the 2011 calendar year accounts may again be deducted, provided that the Company's R&D expenses exceed 25% of state subsidies (proportionate to manufacturer's price) paid on their products and that, within R&D spending, personnel expenses remain above 3% of the same state subsidy amount. Pursuant to the rules of law lower rates of R&D expenses may allow lower deductions.

Entitlement to the deductibility option is judged on the basis of the R&D expenses incurring in the 2011/2012 financial year, consequently, the financial settlement of the deduction allowance can be performed subsequent to the given business year in 2013. Taking into account the R&D expenses incurred in the first quarter of FY2011/2012, 90% of the payment obligation occurring in the first three months of the calendar year 2011, HUF 578mn were accounted as allowance.

The Company's leading product group in the domestic market, Coverex products marketed on the basis of license granted by Servier, reached a turnover of HUF 2.1bn in the first quarter. In the same period, sales revenue of the whole assortment of products licensed from Servier (Coverex-AS, Coverex-AS Komb and AS Komb Forte, Covercard, Adexor MR, Tenaxum, Apadex and Bioparox) totalled HUF 2.9bn. This turnover makes up 33% of the Egis Group's total domestic drug sales over the first quarter.

Sales Revenue – International

The export activity keeps being the core factor of the Group's performance.

In the first quarter, Egis Group generated consolidated international sales revenue at a value of **EUR 70.414 thousand**. This represents a **16% drop** y/y. Quarterly exports in EUR terms depreciated 2% due to EUR being stronger than a year ago. Depreciation affected the Eastern-European exports. Exports to CIS markets (including Russia) reached the value of EUR 36.2mn, 3% over the basis figure. The Egis Group had a turnover of EUR 26.0mn in Eastern Europe. Out of the 20% fall compared to Q1 2010/2011, 6 percentage points were attributable to the strengthening of euro. In the rest of the world Q1 sales remained below the strong year-earlier value by 49%.

Russia

In the first quarter, in Russia, which is reckoned to be the largest export market of the Group, consolidated sales equivalent to EUR 26.0mn were realized, 5% over the comparative figure (RUB 1.08bn also 5% increase y/y). The first three months showed the temporary shrinking of wholesaler stocks of Egis products. As from January 1, 2011, adhering to the regulatory changes in the Russian drug market, the Company is invoicing in rubles to its customers. Switch-over to ruble took place without a hitch, continuity of turnover and payment is ensured also in the new order of settlements. Prices of products figuring on the EDL (Essential Drug List), fixed by authorities since November 2010, have not changed in the reported quarter either. Almost two thirds of turnover of the Egis Group derives from products whose active substances are included in this list.

Ukraine, other CIS markets

Q1 sales in **Ukraine** accounted for EUR 3.5mn, 21% slump compared to the year-earlier quarter (21% lower in USD terms too). Recession in Q1 sales revenue was caused by the temporary shortfall of one product for logistical reasons. The turnover of other products went up 8%. In total, the Group realized sales at a value of EUR 6.7mn in other CIS markets which is 12% higher y/y (the same 12% in USD terms). **Kazakhstan** and **Belarus** saw an especially intensive expansion. The boom is due to the higher extent of state bids vs. basis in Kazakhstan while in Belarus calming down of pharma market after the currency crisis resulted in the boost.

In these markets, the Company, in accord with its partners, strives to retain commercial conditions which promote the uninterrupted development and further considerable turnover expansion in line with their financial possibilities.

Eastern Europe

In the first quarter, the Egis Group's turnover totalled EUR 26.0mn in the Eastern European countries, 20% below the comparative figure. Q1 turnover in **Poland**, in the largest market within this region, came to EUR 10.9mn (PLN 48.1mn, 27% down), with a slump of 35% compared to Q1 2010/2011. Setback of sales is the aggregate consequence of several factors. Euro strengthening depreciated notably the exports of the Egis Group generated in PLN. In addition, wholesalers and retailers have temporarily considerably reduced their purchases to defend themselves against the rapid changes in the price and reimbursement regulation in the Polish drug market.

In the **Czech Republic**, sales were realized at a value of EUR 3.6mn, with a 9% decrease. (The decline in CZK is 7%). In **Slovakia**, Q1 turnover totalled EUR 3.3mn, indicating a 19% drop y/y. In these two markets the lower level of turnover compared to the basis was caused partly by the declining drug prices, partly by shrinking of stocks due to the uncertainties in the market induced by the changes in regulation. In **Romania** sales came to EUR 4.1mn with a 11% development in comparison with Q1 2010/2011 (12% growth in RON terms). Significant delay continues to exist in the Romanian pharmaceutical market which keeps also the Egis Group's receivables on a high level. Rules of law being in force as from October 1, 2009 and amended several times impose payment obligation on pharma industry proportionate to the turnover. Enforcement of law has not taken place yet. On the basis of own calculations the Egis Group made provisions of HUF 203mn in the reported quarter anticipating the payment obligations in the Romanian market. The Egis Group had a turnover of EUR 4.1mn in **other markets of Eastern Europe**, 4% less than a year ago. Taking forex rates of the comparative quarter, sales show a 2% growth.

Rest of the World

In the first quarter, the **export of finished pharmaceuticals** to the rest of the world came to EUR 2.7mn with a 49% fall compared to the basis figure. The **export of drug substances and other products** totalled EUR 5.5mn going down also 49% y/y. Sales declined due to aggressive seasonal effects compared to the strong first three months of 2010/2011.

The quarterly exports generated in the rest of the world accounted for 8.2% of the Egis Group's consolidated revenues. This is 5.6 percentage points below the comparative figure. Deliveries within the confines of Egis and Servier dealings represented the core of turnover.

Three-month consolidated turnover achieved by the Egis Group in the key export markets is shown in the table:

<i>(EUR thousand)</i>	FY2011/2012	FY2010/2011	Change		
Export markets (transactional currency)	Q1	Q1	EUR thousand	% EUR	% TC
Russia (RUB)	25 967	24 655	1 312	5%	5%
Ukraine (USD)	3 512	4 436	-924	-21%	-21%
Other CIS countries (USD)	6 736	6 014	722	12%	12%
Russia and other CIS countries in total	36 215	35 105	1 110	3%	
Poland (PLN)	10 862	16 662	-5 800	-35%	-27%
Czech Republic (CZK)	3 610	3 967	-357	-9%	-7%
Slovakia (EUR)	3 293	4 078	-785	-19%	-19%
Romania (RON)	4 145	3 730	415	11%	12%
Other Eastern European countries	4 121	4 288	-167	-4%	
Eastern Europe in total	26 031	32 725	-6 694	-20%	
Finished pharmaceuticals to other countries	2 656	5 225	-2 569	-49%	
Active ingredients and others	5 512	10 829	-5 317	-49%	
Total export	70 414	83 884	-13 470	-16%	

The average exchange rate in the first quarter was HUF 304.97/EUR, HUF 29.87 or 11% higher y/y which appreciated the Egis Group's quarterly exports by some HUF 1.6bn. Thus, Q1 exports were performed at a value of HUF 21,475mn which lags behind the comparative figure by 7%.

Gross Profit

In the first quarter, consolidated cost of sales represented 40.9% of sales revenue. This is 4.6 percentage points lower than a year ago. The decrease in cost ratio was promoted by the advantageous change in sales structure and favourable shaping of forex rates while the positive effect was moderated by sinking selling prices in numerous markets. Favourably evolving forex rates reduced cost ratio by 2.3 percentage points.

Thus **Gross profit** of the Egis Group reached **HUF 17,961mn** in the first quarter, **3% above** the year-earlier base. This represents 59.1% gross margin.

Operating Profit

In the first quarter, sales, general and administration expenses of the Egis Group lagged behind the comparative figure by 5%. The dynamics of costs is in line with the shaping of the turnover.

Commercial costs (**general selling costs**) decreased 1% in the first quarter in y/y comparison.

Research and development expenses dropped 11% compared to the year-earlier basis. The temporary fall in costs can be explained by the lower level of registration costs and the costs of tests and trials forming part of the developments.

Administrative costs, fell 10% y/y. Among cost items, the ordinary operational costs rose 9% while provisions and other items of value correction were HUF 445mn lower than a year ago.

Three-month consolidated balance of **other operating expenses and income** came to minus HUF 717mn, representing a deterioration of HUF 392mn y/y. The difference is explained mainly by the increase of expenses accounted on the elevated levels of the Hungarian and Romanian pharmaceutical surtax. In the first quarter, balance of items accounted in relation with the different state-run payment obligations, charging the pharmaceutical industry, was minus HUF 609mn. Out of this, HUF 406mn was the balance of expenditures and allowances accounted on obligations in Hungary, HUF 203mn was the value of expenditures in Romania. Other accounts showed HUF 108mn surplus on the expenditure side. May we remind you herewith that the Company already presents the local business tax (LBT) as part of the profit tax.

Thus, **consolidated operating profit** of the first quarter reached **HUF 5,522mn**, **15% more** than in the same period of the previous year.

Favourable operating profit was promoted mainly by the development of exchange rates and by low cost level. Further contribution also has been made by the accounting of pro rata R&D based recoveries.

Profit before Taxation

In the first quarter of the financial year, Egis Group's consolidated profit resulting from financial activities together with the share of results of associated companies showed, in total, a positive HUF 189mn. This is lower by HUF 292mn than in the same period of the previous year. The financial result was positively affected by the exchange rates, playing an important role in the activities of the Egis Group, having a more advantageous HUF relative level over the period and at the end of the quarter.

Among the main items of financial activities and associated companies of the reported quarter, net interest income accounted for HUF 461mn, impact of exchange rates (exchange rate gain/loss and forex hedge positions) was, in total, HUF 795mn (out of which HUF 47mn was realized) while other accounts showed minus HUF 1,067mn. The latter was determined by the share of results of associated companies at a value of minus HUF 1,026mn in the highlighted quarter. More specifically, it was determined by the Company's share of loss in value accounted on the receivables at Hungaropharma.

As a result of all these factors, **consolidated pre-tax profit** of the first quarter amounted to **HUF 5,711mn**, 8% higher than the year-earlier basis.

Net Profit

Egis Pharmaceuticals PLC is entitled to corporate income tax allowance on the basis of considerable investments realized in production facilities between 2005 and 2011. Up to the level of the allowance value, the Company enjoys a tax allowance of 80% out of the 19% corporate income tax of general standard. Other companies of the Egis Group pay corporate income tax according to the general regulations being in force in the individual countries.

Besides the corporate income tax, due to the change in the accounting and general sector-specific practice the Company presents the local business tax (LBT) as part of the profit tax. The value of local taxes came to HUF 374mn in the quarter.

In the first quarter, consolidated net profit came to **HUF 5,333mn**, **14% higher** than a year ago.

Assets vs. Equity & Liabilities

Consolidated total sum of **assets vs. equity & liabilities** on the balance sheet of the Egis Group amounted to HUF 190,498mn at the end of the period, representing 9% rise y/y and practically the same as the closing value of the previous business year.

Value of **intangible assets** is 7% less than last year and 4% lower than the opening value of the business year. Value of **property, plant and equipment** rose 8% over a year while the value decreased 1% in the reported quarter. More specifically, net value of land, buildings, machinery and net value of equipment has not changed in the last three months, while value of item 'Construction in progress' decreased 14%.

Value of invested financial assets has decreased 49% over the past year due to the deterioration effect of the loss in value accounted by Hungaropharma on its receivables, representing 23% fall compared to the opening value of the quarter.

On December 31, 2011, value of **inventories** of the Group was 1% lower than the value at the end of the previous business year, but it has exceeded by 6% the closing value on September 30, 2011. The quarterly rise has mainly appeared in the growth of finished products inventories, which is due to the lower than anticipated sales in Eastern Europe. The value of **trade receivables** rose 29% over the last year while the growth came to 4% in the highlighted quarter.

At the end of the reported period, **cash and cash equivalents and other financial assets** of the Egis Group in total amounted to HUF 32,979mn, 21% more than a year ago, at the same time 8% less than the closing value of the last business year. The quarterly decrease was primarily caused by seasonality while the yearly increase was mainly due to the profitable export-driven activity and the strict working capital management.

Equity of the Group at the end of the reported period was HUF 166,494mn, increasing 9% over the year and 3% in the reported quarter. Equity per share grew to HUF 21,385.

Liabilities continued to represent a minor ratio, 13% in the account of equity & liabilities of the Group at the end of the highlighted period. Value of **non-current liabilities** increased 4% over the past year while value of **current liabilities** dropped 21%. More specifically, value of **trade payables** decreased 31%.

Other Information

Headcount, Capital Expenditure

The total number of **full-time employees** of the Egis Group was 3,850 as at December 31, 2011, that is 61 persons less than at the end of the previous business year. Out of the consolidated headcount, 2,577 people worked at Egis Pharmaceuticals PLC in Hungary, 38 people at the Hungarian subsidiaries, 803 in the foreign commercial offices and 432 at the foreign subsidiaries of the Group.

The number of full-time employees of Egis Pharmaceuticals PLC (stand-alone) on labour law basis was 2,579 at the end of the quarter.

In the first quarter of the reported financial year, **capital expenditure** of the Egis Group totalled HUF 1,885mn, 23% less than the year before. Within this, capex of Egis Pharmaceuticals PLC came to HUF 1,754mn while capex of subsidiaries totalled HUF 131mn.

Segment Information

Segment information about Egis Group's activity is contained in the data sheets enclosed. Dominant operation segment of the Group is '**production and sale of pharmaceutical products**' which is identical with Egis Pharmaceuticals PLC's activity.

Shares, Ownership Structure

The Company's **share capital** as at December 31, 2011 invariably equalled HUF 7,785,715 thousand, the same as a year ago. Share capital consists of 7,785,715 issued and fully paid dematerialized shares of registered value of HUF 1,000 per share, carrying equal voting rights. The shares are listed on the Budapest Stock Exchange in category 'A'.

There was no significant change in the **ownership structure** of the Company. The French company Arts et Techniques du Progrès (Servier) continues to own 50.91% of shares while the remaining stock is in the possession of other shareholders. One further investor, Tradewinds Global Investors, LLC has higher than 10% ownership of shares.

Contracts, Obligations

In order to secure export revenues, Egis Pharmaceuticals PLC regularly takes **forex hedge positions**. At the closing date of the accounts solely forex Russian rouble forward sell agreements were recorded among the open positions of the Company, schedule to expire until June, 2012. The result of the realized forex hedge transactions during the reported period as well as the value of open positions at the closing date of the accounts are included in the accounts of this report.

The October - December 2011 rate of the **payment obligation** stipulated in the act on pharmaceutical market is indicated in the accounts at a value of HUF 984mn as expenditure. Within this sum, the October value was calculated on actual data while the amount for November - December reflects the estimation of the Company. The Company fulfilled the payment obligations that are stipulated in the act on pharmaceutical market according to their due-date, within the specified time.

As announced in the previous reports of the Company, according to the changing rules of law, out of the payment obligations prescribed by the act on pharmaceutical market, the Company accounted its expenditures and the presumably enforceable allowances related to R&D expenditure. The Company is going to have the possibility to enforce HUF 1,184mn in 2012 calendar year as allowance from payment obligations effected over 2010.

According to the act modification passed in December 2011 by the Parliament up to 90% can be deducted as allowance from the Company's payments obligations which had been made in the 2011 calendar year as a function of their R&D spending in 2011/2012 business year. The deduction can be realized after the closing of 2011/2012 business year (from the beginning of 2013 calendar year). By virtue of the level of R&D expenses in the first quarter of the reported business year the Company is going to be entitled to 90% deduction. Accordingly, the Company put into deduction HUF 578mn. Thus, at the end of the reported quarter the Company records HUF 1,762mn deduction.

In February 2010, Egis Pharmaceuticals PLC signed an **agreement with Celltrion**/South Korea for distribution of eight biosimilar products in the strategic markets of Egis Pharmaceuticals PLC. Under the general contract, also the product supply agreements for the first two products have been signed. USD 3.2mn as advance payment was effected by Egis Pharmaceuticals PLC in the first quarter, which will be deducted on delivery of the products.

The Company had no **other significant outstanding liabilities** at the end of the period.

No **bonds** were issued by the Company.

Others

In the highlighted quarter, there was one single change **in the executive management of the Company**. Dr Imre Szentpéteri has been appointed as director of R&D from October 1, 2011.

The Company holds no **treasury shares**.

Disclosures

Between October 1, 2011 and December 31, 2011, the following information was published by Egis Pharmaceuticals PLC:

November 2, 2011	Amendment to the Accounting Policy
November 9, 2011	Quarterly Report Full Business Year 2010/2011
December 16, 2011	Invitation to the Annual General Meeting (AGM) of Shareholders to be held on January 25, 2012
December 16, 2011	Remuneration Statement

In addition to the above announcements, the Company, in effort to meet the rules set in Point (9) Section 54 of the modified Capital Market Act (CXX/2001), has given information monthly on voting rights attached to its shares and on the share capital.

Enclosures

- Data sheets

Appendices

- Financial statements of Egis Pharmaceuticals PLC for the first quarter of the 2011/2012 business year
- Export sales revenue of Egis Pharmaceuticals PLC in the first quarter of the 2011/2012 business year

STATEMENT

The present report of Egis Pharmaceuticals Public Limited Company (hereinafter 'the Company') on the first quarter of the 2011/2012 business year together with the attached financial statements gives true and fair view of the position of the Company and its consolidated companies.

Budapest, February 8, 2012

Egis Pharmaceuticals Public Limited Company

A handwritten signature in blue ink, appearing to read "Hodász István Balázs".

Dr HODÁSZ István Balázs
Chief Executive Officer

Company name: Egis Pharmaceuticals PLC
Company address: H-1106 Bp., Keresztúri út 30-38.
Sector: pharmaceuticals
Reporting period: three months 2011/2012

Telephone: +36 1 803 5555
Fax: +36 1 803 5529
E-mail address: mailbox@egis.hu
IR manager: CSÁNY, László

PK1. General information about financial data

Audited Yes No

Consolidated Yes No

Accounting principles Hungarian IFRS Other

PK2. Consolidated companies

Name	Equity/Registered Capital	Interest held (%)	Voting right	Classification ¹
Egis Polska Sp.z o.o.	PLN 17,860,000	100	100 %	L
Egis Polska Dystrybucja Sp.z o.o.	PLN 20,000,000	100	100 %	L
Egis Praha spol. s r.o.	CZK 82,640,000	100	100 %	L
Egis Slovakia spol. s r.o.	EUR 3,196,242	100	100 %	L
Egis Rompharma S.R.L.	RON 10,000	100	100 %	L
Egis Bulgaria EOOD	BGN 5,000	100	100 %	L
Egis Ilaclari Limited Sirketi	TRY 19,160,000	100	100 %	L
Medimpex Kereskedelmi Zrt.	HUF 598,000,000	100	100 %	L
Medimpex Irodaház Ingatlankezelő Kft.	HUF 606,440,000	50	50 %	T
Egis Pharmaceuticals U.K. Ltd.	GBP 1,000	100	100%	L
OOO Egis RUS	RUB 2,500,000	100	100%	L

¹ Full (L), Associated (T)

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

PK3. Consolidated Statement of Financial Position

in accordance with IFRS

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X
	30 Sept 2011 Audited	31 Dec 2011 Unaudited	Index (2/1)	
	1	2		
ASSETS				
Intangible assets	4 101	3 946	96,2	
Property, plant and equipment	69 347	68 557	98,9	
Land and buildings	34 340	34 463	100,4	
Plant, machinery and equipment	25 482	25 388	99,6	
Vehicles	3 327	3 358	100,9	
Construction in progress	6 198	5 348	86,3	
Investment properties	314	651	207,3	
Investments in associates	3 719	2 693	72,4	
Other non-current financial assets	570	612	107,4	
Deferred tax asset	452	552	122,1	
Inventories	35 836	37 835	105,6	
Work-in-progress and semi-finished products	16 348	17 321	106,0	
Finished goods	8 000	9 199	115,0	
Raw materials	7 526	6 770	90,0	
Goods for resale	3 962	4 545	114,7	
Net trade receivables and other current assets	40 551	42 673	105,2	
Trade receivables	29 995	31 184	104,0	
Taxes receivable	2 448	1 336	54,6	
Advance payments to suppliers	5 816	6 681	114,9	
Other receivables	2 292	3 472	151,5	
Other current financial assets	10 570	11 883	112,4	
Cash and cash equivalents	25 260	21 096	83,5	
Cash in bank	24 961	20 746	83,1	
Cash on hand	299	350	117,1	
TOTAL ASSETS	190 720	190 498	99,9	

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

Consolidated Statement of Financial Position (continued)

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X

	30 Sept 2011 Audited	31 Dec 2011 Unaudited	Index (2/1)
	1	2	

<u>EQUITY AND LIABILITIES</u>			
Equity	161 639	166 494	103,0
Share capital	7 786	7 786	100,0
Share premium	2 239	2 239	100,0
Fair valuation reserve	15	61	406,7
Translation difference	898	1 308	145,7
Retained earnings	150 701	155 100	102,9
Non-current liabilities	4 261	4 452	104,5
Other non-current financial liabilities	3 017	3 178	105,3
Provisions	1 244	1 274	102,4
Current liabilities	24 820	19 552	78,8
Other current financial liabilities	159	550	345,9
Provisions	2 060	1 913	92,9
Trade payables	14 253	9 820	68,9
Salaries payable	988	958	97,0
Taxes and duties payable	1 555	1 456	93,6
Other short term liabilities	5 805	4 855	83,6
TOTAL EQUITY AND LIABILITIES	190 720	190 498	99,9

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

PK4. Consolidated Income Statement in accordance with IFRS

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X
		Three months ended 31 Dec 2010 Restated	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
		1	2	
Domestic sales		8 838	8 917	100,9
Export sales		23 077	21 475	93,1
Sales		31 915	30 392	95,2
Cost of sales		14 509	12 431	85,7
Gross profit		17 406	17 961	103,2
General selling costs		7 145	7 099	99,4
Research and development expenses		2 761	2 470	89,5
Administrative costs		2 386	2 153	90,2
Administrative and distribution expenses		12 292	11 722	95,4
Other operating expenses		623	1 043	167,4
Other operating income		298	326	109,4
Operating profit		4 789	5 522	115,3
Foreign exchange gains, net		465	1 591	342,2
Interest income		278	484	174,1
Other financial income		5	2	40,0
Finance income		748	2 077	277,7
Loss on derivative transactions, net		116	796	686,2
Interest expense		21	23	109,5
Other financial expense		35	43	122,9
Finance costs		172	862	501,2
Profit from financial activities		576	1 215	210,9
Share of results of associated companies		-95	-1 026	1 080,0
Profit before taxation		5 270	5 711	108,4
Taxation		594	378	63,6
Net profit		4 676	5 333	114,1
Basic and diluted earnings per share (HUF)		601	685	114,1

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

Consolidated Statement of Comprehensive Income

in accordance with IFRS

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X
		Three months ended	Three months ended	Index
		31 Dec 2010	31 Dec 2011	(2/1)
		Unaudited	Unaudited	
		1	2	
Profit for the year		4 676	5 333	114,1
Exchange differences on translation of foreign operations		59	410	694,9
Change in the fair value of available-for-sale financial assets		11	46	418,2
Total comprehensive income for the year		4 746	5 789	122,0

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

PK5. Consolidated Statement of Cash Flows in accordance with IFRS

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X

	Three months ended 31 Dec 2010 Restated	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
	1	2	

CASH FLOWS FROM OPERATING ACTIVITIES

Profit before taxation	5 270	5 711	108,4
Depreciation and amortization	2 259	2 525	111,8
Impairment of intangible and tangible assets, net	0	6	
Net interest income	-257	-461	179,4
Profit on disposal of fixed assets	-42	-96	228,6
Unrealised foreign exchange loss	71	546	769,0
Fair valuation of financial instruments	311	476	153,1
Increase / decrease (-) in provision for liabilities	169	-117	
Write-down of employee loans	4	5	125,0
Share of results of associated companies	95	1 026	1 080,0
Decrease / increase (-) in inventories	704	-1 999	
Increase in net trade receivables and other current assets	-51	-2 122	4 160,8
Decrease in trade and other payables	-3 925	-6 446	164,2
Net tax paid	-535	-478	89,3
Cash flows from / net cash used in operating activities	4 073	-1 424	

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of intangibles and property, plant and equipment	-2 438	-1 885	77,3
Proceeds from sale of intangibles and property, plant and equipment	62	126	203,2
Interest received	278	484	174,1
Decrease / increase (-) in securities	414	-1 409	
Loans given	-14	-3	21,4
Repayment of loans given	8	17	212,5
Net cash used in investing activities	-1 690	-2 670	158,0

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

Consolidated Statement of Cash Flows (continued)

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X

	Three months ended 31 Dec 2010 Restated	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
	1	2	

CASH FLOWS FROM FINANCING ACTIVITIES

Repayment of borrowings	-130	-47	36,2
Proceeds from borrowings	1	0	
Interest paid	-21	-23	109,5
Net cash used in financing activities	-150	-70	46,7
Net change in cash and cash equivalents	2 233	-4 164	
Cash and cash equivalents at the beginning of the period	17 973	25 260	140,5
Cash and cash equivalents at the end of the period	20 206	21 096	104,4

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

Consolidated Statement of Changes in Equity

in accordance with IFRS

Currency	HUF	X	EUR			
Unit	1 000		1 000 000			X
	Share capital	Share premium	Fair valuation reserve	Translation difference	Retained earnings	Total
30 September 2010	7 786	2 239	26	1 021	138 050	149 122
Net profit					4 676	4 676
Dividends paid					-934	-934
Fair value difference on available-for-sale investments			11			11
Translation difference				59		59
31 December 2010	7 786	2 239	37	1 080	141 792	152 934
30 September 2011	7 786	2 239	15	898	150 701	161 639
Net profit					5 333	5 333
Dividends paid					-934	-934
Fair value difference on available-for-sale investments			46			46
Translation difference				410		410
31 December 2011	7 786	2 239	61	1 308	155 100	166 494

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

Segment Information

in accordance with IFRS

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X

	Pharmaceutical manufacturing and sales		Pharmaceutical wholesale and retail		Inter-segment eliminations		Total	
	3 months ended 31 Dec 2010	3 months ended 31 Dec 2011	3 months ended 31 Dec 2010	3 months ended 31 Dec 2011	3 months ended 31 Dec 2010	3 months ended 31 Dec 2011	3 months ended 31 Dec 2010	3 months ended 31 Dec 2011
SALES								
External sales	24 525	23 777	7 390	6 615	0	0	31 915	30 392
Inter-segment sales	5 716	6 812	2 006	1 861	-7 722	-8 673	0	0
Total sales	30 241	30 589	9 396	8 476	-7 722	-8 673	31 915	30 392
RESULT								
Operating profit (restated)	5 135	6 635	-30	-125	-316	-988	4 789	5 522
Financial result	-	-	-	-	-	-	576	1 215
Share of results of associated companies	0	0	-95	-105	0	0	-95	-1 026
Taxation (restated)	-	-	-	-	-	-	-594	-378
Net profit	-	-	-	-	-	-	4 676	5 333
OTHER INFORMATION								
Purchase of intangibles, property plant and equipment	2 261	1 754	177	131	0	0	2 438	1 885
Impairment	0	6	0	0	0	0	0	6
Depreciation and amortization	2 102	2 362	157	163	0	0	2 259	2 525

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name:	Egis Pharmaceuticals PLC	Telephone:	+36 1 803 5555
Company address:	H-1106 Bp., Keresztúri út 30-38.	Fax:	+36 1 803 5529
Sector:	pharmaceuticals	E-mail address:	mailbox@egis.hu
Reporting period:	three months 2011/2012	IR manager:	Csány László

Segment Information (continued)

Currency	HUF	X	EUR	
Unit	1 000		1 000 000	X

	Pharmaceutical manufacturing and sales		Pharmaceutical wholesale and retail		Inter-segment eliminations		Total	
	30 Sept 2011	31 Dec 2011	30 Sept 2011	31 Dec 2011	30 Sept 2011	31 Dec 2011	30 Sept 2011	31 Dec 2011
Investments in associates	2 610	2 610	1 109	83	0	0	3 719	2 693
Other segment assets	180 529	182 888	26 312	26 037	-19 840	-21 120	187 001	187 805
Total assets	183 139	185 498	27 421	26 120	-19 840	-21 120	190 720	190 498
Liabilities	24 771	20 112	17 712	17 575	-13 402	-13 683	29 081	24 004

	Sales		Purchase of intangibles, property, plant and equipment		Total intangibles and property, plant and equipment	
	3 months ended 31 Dec 2010	3 months ended 31 Dec 2011	3 months ended 31 Dec 2010	3 months ended 31 Dec 2011	30 Sept 2011	31 Dec 2011
Hungary	8 838	8 917	2 362	1 515	70 648	70 015
Russia and other CIS countries	9 607	11 061	0	242	1 663	1 669
Eastern Europe	9 042	7 928	76	128	1 451	1 470
Others	4 428	2 486	0	0	0	0
Total	31 915	30 392	2 438	1 885	73 762	73 154

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Egis Pharmaceuticals PLC
Company address: H-1106 Bp., Keresztúri út 30-38.
Sector: pharmaceuticals
Reporting period: three months 2011/2012

Telephone: +36 1 803 5555
Fax: +36 1 803 5529
E-mail address: mailbox@egis.hu
IR manager: CSÁNY, László

PK6. Significant off-balance sheet items

Description	Value (HUF)
---	---

RS1. Ownership structure, ratio of holdings and votes

Description of owner	Total share capital			
	1 October 2011	31 December 2011		
	%	qty	%	qty
Domestic institution/company	8.28	644,696	7.78	605,772
Foreign institution/company	87.69	6,827,115	88.50	6,890,874
Domestic individual	3.31	257,511	3.05	237,647
Foreign individual	0.71	55,578	0.65	50,607
Employees, senior officers	0.01	400	0.01	400
Treasury shares	0.00	0	0.00	0
Government held owner	0.01	415	0.01	415
International Development Institutions	0.00	0	0.00	0
Other	0.00	0	0.00	0
TOTAL	100.00	7,785,715	100.00	7,785,715

Remarks: (1) Listed series equivalent with total share capital,
 (2) ratio of holdings and votes are equivalent.

RS2. Volume (qty) of treasury shares held in the period

	1 Oct 2011	31 Dec 2011
Company	--	--
Subsidiaries	--	--
TOTAL	--	--

RS3. List and description of shareholders with more than 5% ownership (31 December 2011)

Name	Nationality	Activity	Quantity	Interest (%)	Remarks
Arts et Techniques du Progrès (Servier)	Foreign	Business organisation	3,963,922	50.91	Professional investor
Tradewinds Global Investors, LLC	Foreign	Business organisation	(3)	(3)	Financial investor

Remarks: (1) Ratio of holdings and votes are equivalent,
 (2) Listed series equivalent with total share capital,
 (3) No details available for the Company

Company name: Egis Pharmaceuticals PLC
Company address: H-1106 Bp., Keresztúri út 30-38.
Sector: pharmaceuticals
Reporting period: three months 2011/2012

Telephone: +36 1 803 5555
Fax: +36 1 803 5529
E-mail address: mailbox@egis.hu
IR manager: CSÁNY, László

TSZ1. Changes in the headcount (number of persons) employed

	End of reference period (31 December 2010)	Current period opening (1 October 2011)	Current period closing (31 December 2011)
Company	2,597	2,625	2,577
Group	3,803	3,915	3,850

Remark: employees eligible for retired status, and having full-time employment are recorded by Egis Pharmaceuticals PLC as full-time employees. The headcount includes also employees who are in possession of valid labour contract, but having incapability for longer than 30 days.

TSZ2. Senior officers, strategic employees (31 December 2011)

Type	Name	Position	Beginning of assignment	End or termination of assignment	No. of shares held
IT	Dr Jean-Philippe SETA	chairman	29.01.1996.	*	0
IT	Christian BAZANTAY	member	29.01.1996.	*	0
IT	Nicolas BOUTS	member	28.01.2009.	*	0
IT	Ange DIAZ	member	29.01.1996.	*	0
IT	DIETZ András	member	30.01.2008.	*	0
SP		Technical Dir.	01.10.2007.	undetermined	0
IT	GÁL Péterné	member	25.01.2006.	*	0
IT	Dr HODÁSZ István	member	25.01.2006.	*	0
SP		CEO	01.10.2009.	undetermined	0
IT	Yves LANGOURIEUX	member	29.01.1996.	*	0
IT	Olivier LAUREAU	member	28.01.2009.	*	0
IT		member	27.01.2011.	*	0
SP	POROSZLAI Csaba	CFO	01.02.2011.	undetermined	0
IT	Dr VERESS József	member	31.12.1991.	*	0
FB	KOVÁCS Andor	chairman	31.12.1991.	**	0
FB	BÁLINT Konrádné dr.	member	31.12.1991.	**	0
AB		member	24.01.2007.	**	0
FB	GUETH János	member	27.01.2010.	**	400
FB	LABRITZ Béla	member	27.01.2010.	**	0
FB	NAGY Imre	member	04.04.2001.	**	0
FB	Georges RADVÁNYI	member	29.04.1998.	**	0
AB		member	24.01.2007.	**	0
FB	Dr RESZEGI László	member	31.12.1991.	**	0
AB		chairman	24.01.2007.	**	0
SP	Dr MÁZSÁR Péter	Dir. of Comm.	01.10.2009.	undetermined	0
SP	Dr SZENTPÉTERI Imre	Dir. of R&D	01.10.2011.	undetermined	0
SP	Dr SZEMERÉDI Katalin	Dir. of HR	01.04.2005.	undetermined	0
Own share property TOTAL					400

IT = Board of Directors, FB = Supervisory Board, AB = Audit Committee, SP = holder of Strategic Position (management)

* Date of AGM voting on FY 2010/2011 results

** Date of AGM voting on FY 2011/2012 results

Statement of Financial Position of Egis Pharmaceuticals PLC in accordance with IFRS

<i>HUF million</i>	30 Sept 2011 Audited	31 Dec 2011 Unaudited	Index (2/1)
	1	2	
ASSETS			
Intangible assets	4 003	3 851	96,2
Property, plant and equipment	63 572	63 089	99,2
Land and buildings	30 085	30 222	100,5
Plant, machinery and equipment	25 235	25 151	99,7
Vehicles	2 430	2 408	99,1
Construction in progress	5 822	5 308	91,2
Equity investments	7 612	7 866	103,3
Other non-current financial assets	1 763	1 842	104,5
Deferred tax asset	73	88	120,5
Inventories	33 949	35 727	105,2
Work-in-progress and semi-finished products	16 348	17 321	106,0
Finished goods	6 794	8 148	119,9
Raw materials	7 523	6 770	90,0
Goods for resale	3 284	3 488	106,2
Net trade receivables and other current assets	40 209	43 904	109,2
Trade receivables	30 141	32 755	108,7
Taxes receivable	2 122	959	45,2
Advance payments to suppliers	5 680	6 760	119,0
Other receivables	2 266	3 430	151,4
Other current financial assets	10 597	11 895	112,2
Cash and cash equivalents	21 361	17 236	80,7
Cash in bank	21 350	17 227	80,7
Cash on hand	11	9	81,8
TOTAL ASSETS	183 139	185 498	101,3

Prepared in accordance with IAS 34 Interim Financial Reporting.

Statement of Financial Position of Egis Pharmaceuticals PLC (continued)

<i>HUF million</i>	30 Sept 2011 Audited	31 Dec 2011 Unaudited	Index (2/1)
	1	2	
<u>EQUITY AND LIABILITIES</u>			
Equity	158 368	165 386	104,4
Share capital	7 786	7 786	100,0
Share premium	2 239	2 239	100,0
Fair valuation reserve	15	61	406,7
Retained earnings	148 328	155 300	104,7
Non-current liabilities	1 207	1 235	102,3
Provisions	1 207	1 235	102,3
Current liabilities	23 564	18 877	80,1
Other current financial liabilities	1	396	39 600,0
Provisions	2 053	1 905	92,8
Trade payables	14 580	10 030	68,8
Salaries payable	912	901	98,8
Taxes and duties payable	1 045	927	88,7
Other short term liabilities	4 973	4 718	94,9
TOTAL EQUITY AND LIABILITIES	183 139	185 498	101,3

Prepared in accordance with IAS 34 Interim Financial Reporting.

Income Statement of Egis Pharmaceuticals PLC

in accordance with IFRS

<i>HUF million</i>	Three months ended 31 Dec 2010 Restated	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
	1	2	
Domestic sales	8 502	8 567	100,8
Export sales	21 739	22 022	101,3
Sales	30 241	30 589	101,2
Cost of sales	13 089	12 050	92,1
Gross profit	17 152	18 539	108,1
General selling costs	7 060	6 755	95,7
Research and development expenses	2 761	2 470	89,5
Administrative costs	1 951	2 196	112,6
Administrative and distribution expenses	11 772	11 421	97,0
Other operating expenses	511	758	148,3
Other operating income	266	275	103,4
Operating profit	5 135	6 635	129,2
Foreign exchange gains, net	574	2 053	357,7
Interest income	281	472	168,0
Other financial income	4	2	50,0
Finance income	859	2 527	294,2
Loss on derivative transactions, net	116	796	686,2
Other financial expense	38	42	110,5
Finance costs	154	838	544,2
Profit from financial activities	705	1 689	239,6
Profit before taxation	5 840	8 324	142,5
Taxation	494	418	84,6
Net profit	5 346	7 906	147,9
Basic and diluted earnings per share (HUF)	687	1 015	147,9

Prepared in accordance with IAS 34 Interim Financial Reporting.

Statement of Comprehensive Income of Egis Pharmaceuticals PLC

in accordance with IFRS

<i>HUF million</i>	Three months ended 31 Dec 2010 Unaudited	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
	1	2	
Profit for the year	5 346	7 906	147,9
Change in the fair value of available-for-sale financial assets	11	46	418,2
Total comprehensive income for the year	5 357	7 952	148,4

Prepared in accordance with IAS 34 Interim Financial Reporting.

Statement of Cash Flows of Egis Pharmaceuticals PLC

in accordance with IFRS

<i>HUF million</i>	Three months ended 31 Dec 2010 Restated	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
	1	2	
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before taxation	5 840	8 324	142,5
Depreciation and amortization	2 102	2 362	112,4
Impairment of intangible and tangible assets, net	0	6	
Net interest income	-281	-472	168,0
Profit on disposal of fixed assets	-26	-45	173,1
Unrealised foreign exchange gain	-25	-292	1 168,0
Fair valuation of financial instruments	311	476	153,1
Increase / decrease (-) in provision	168	-120	
Write-down of employee loans	4	5	125,0
Increase in inventories	-191	-1 777	930,4
Increase in net trade receivables and other current assets	-1 355	-3 695	272,7
Decrease in trade and other payables	-3 442	-5 868	170,5
Net tax paid	-451	-432	95,8
Cash flows from / net cash used in operating activities	2 654	-1 528	
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of intangibles and property, plant and equipment	-2 261	-1 754	77,6
Proceeds from sale of intangibles and property, plant and equipment	37	66	178,4
Interest received	281	472	168,0
Decrease / increase (-) in securities	414	-1 409	
Loans given	-14	-3	21,4
Repayment of loans given	8	31	387,5
Net cash used in investing activities	-1 535	-2 597	169,2

Prepared in accordance with IAS 34 Interim Financial Reporting.

Statement of Cash Flows of Egis Pharmaceuticals PLC (continued)

<i>HUF million</i>	Three months ended 31 Dec 2010 Restated	Three months ended 31 Dec 2011 Unaudited	Index (2/1)
	1	2	
CASH FLOWS FROM FINANCING ACTIVITIES			
Increase in short term borrowings	1	0	
Cash flows from financing activities	1	0	
Net change in cash and cash equivalents	1 120	-4 125	
Cash and cash equivalents at the beginning of the period	15 292	21 361	139,7
Cash and cash equivalents at the end of the period	16 412	17 236	105,0

Prepared in accordance with IAS 34 Interim Financial Reporting.

Statement of Changes in Equity of Egis Pharmaceuticals PLC in accordance with IFRS

<i>HUF million</i>	Share capital	Share premium	Fair valuation reserve	Retained earnings	Total
30 September 2010	7 786	2 239	26	134 285	144 336
Net profit				5 346	5 346
Fair value difference on available-for-sale investments			11		11
Dividends paid				-934	-934
31 December 2010	7 786	2 239	37	138 697	148 759
30 September 2011	7 786	2 239	15	148 328	158 368
Net profit				7 906	7 906
Fair value difference on available-for-sale investments			46		46
Dividends paid				-934	-934
31 December 2011	7 786	2 239	61	155 300	165 386

Prepared in accordance with IAS 34 Interim Financial Reporting.

Export Sales Revenue of Egis Pharmaceuticals PLC

non-consolidated

<i>EUR thousand</i>	2011/2012	2010/2011		Change
Export markets	Three months	Three months	EUR	%
Russia	25 685	24 356	1 329	5
Ukraine	3 493	4 326	-833	-19
Other CIS countries	6 736	6 014	722	12
Russia and other CIS countries in total	35 914	34 696	1 218	4
Poland	13 150	12 444	706	6
Czech Republic	3 610	3 952	-342	-9
Slovakia	3 384	4 102	-718	-18
Romania	4 481	3 809	672	18
Other Eastern European countries	3 588	3 982	-394	-10
Eastern Europe in total	28 213	28 289	-76	0
Finished pharmaceuticals to other countries	2 656	5 225	-2 569	-49
Active ingredients and others	5 515	10 831	-5 316	-49
Total export	72 298	79 041	-6 743	-9